Neuron-derived extracellular vesicles (NDEVs) represent a novel, minimally invasive biomarker platform to assess CNS insulin signaling activity in clinical cohorts.
PPAR agonist pioglitazone induces broad activation of key metabolic proteins (GSK3, mTOR, RPS6) within the Akt-mTOR pathway in patients with unremitted depression.
GLP1 receptor agonist liraglutide enhances CNS insulin signaling evidenced by increased phosphorylation of Akt and mTOR in middle-aged adults at genetic risk for Alzheimer’s disease.
These CNS biomarker changes appear at least partially independent of peripheral insulin and glucose metabolism, suggesting direct central effects.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
